Lung Cancer Therapeutics Market Revenue, Leading Companies, Company Technology / Innovation, Diagnostic Testing Volume, Adoption Rates, Pricing Metrics, Supply Chain Performance, Competitive Positioning, and Industry Trends

Revenue, 2026

USD 38.23 Bn

Forecast Year, 2035

USD 76.65 Bn

CAGR, 2026 - 2035

8.04%

Report Coverage

Global

What is the Lung Cancer Therapeutics Market Size?

The global lung cancer therapeutics market size is valued at USD 35.37 billion in 2025 and is predicted to increase from USD 38.23 billion in 2026 to approximately USD 76.65 billion by 2035, expanding at a CAGR of 8.04% from 2026 to 2035.

Lung Cancer Therapeutics Market Key Takeaways

• North America led the global market with the highest market share of 31% in 2025.
• By therapy, the targeted therapy segment is estimated to capture the biggest revenue share of 50% in 2025.
• By lung cancer type, the non-small cell lung cancer segment is predicted to register the maximum market share in 2025.
• By distribution channel, the hospital pharmacies segment is estimated to hold the highest market share in 2025.

Lung Cancer Therapeutics Market Growth Factors

Cancer is a gene related disease that cells grow abnormally during the mutation. These cells flow from the original site to other sites through blood and lymph. Lungs cancer is the most prevailing type of cancer across the globe and it affects the lung tissues. Lungs cancer creates difficulties in supplying oxygen to the blood. Lungs cancer has the highest mortality rate among both the male and female population and the majority of the lungs cancer are the non-small cell lung cancer.

The global lung cancer therapeutics market is projected to witness a significant growth owing to the surging prevalence of lungs cancer among the global population. According to the GLOBOCAN 2020 estimates by the International Agency for Research on Cancer, there were around 19.3 million new cases of cancer recorded in 2020 and around 11.4% of it was lungs cancer. Lung cancer was the leading cause of death with around 18% or 1.8 million global deaths in 2020. The incidences of lung cancer are growing rapidly across the globe owing to the increasing prevalence of smoking and exposure to second hand smoke.

Market Outlook

• Start-Up Ecosystem
  The start-ups are introducing precision-focused therapies to the healthcare sector, and their immunotherapy and next-generation drug delivery are bringing new approaches into consideration for the existing giants. The contracts and acquisition deals have fuelled the growth of the start-ups.
• Industry Growth Overview
  The industry growth is massive as a number of clinical trials and research are conducted by numerous giants of the healthcare industry. Whereas, the trend of the term ‘precision treatment' and regulatory challenges are provoking the success of the industry for the patient's betterment as a whole.

Market Scope

Segments Insights

Therapy Insights

Based on the therapy, the targeted therapy was the leading segment that accounted for over 50% of the market share in 2025. Targeted therapy has gained a significant traction among the lung cancer patients. The rapid growth of the biopharmaceutical industry and the rising research and development expenses has resulted in the development of advanced targeted therapeutics to treat lung cancer. The targeted therapy can effectively treat the cancer cells without altering the normal cells of the body. This results in minimal side-effects and eliminates the chances of reoccurrence and deaths. The rising healthcare expenditure along with the growing awareness regarding the availability of advanced gene therapies that can cure the traditionally non-curable diseases has significantly fueled the growth of the targeted therapy across the globe.

The immunotherapy is anticipated to be the most opportunistic segment during the forecast period. The immunotherapy uses the immunity system to eliminate, prevent, and control the cancer causing cells in the body. It enhances the immune system and educates the immune system to identify the cancer cells and attack those specific cells to treat the lung cancer. Immunotherapy is considered to be a smart way to prevent cancer cells and it is rapidly gaining traction among the cancer patients. Therefore, the immunotherapy is anticipated to be the fastest-growing segment in the global lung cancer therapeutics market.

Lung Cancer Type Insights

Based on the lung cancer type, the market is divided into non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumor. The non-small cell lung cancer segment dominated the global lung cancer therapeutics market in 2025. This growth is primarily attributed to the increased prevalence of non-small cell lung cancer among the population. The treatment of the non-small cell lung cancer totally depends on the stages of this cancer. It is estimated that around 80% of the lung cancer are non-small cell lung cancer and hence the demand for the lung cancer therapeutics to cure this type of lung cancer has propelled the growth of this segment in the global lung cancer therapeutics market.

The small cell lung cancer is expected to be the fastest-growing owing to the growing prevalence of smoking and as a result the rising prevalence of small cell lung cancer. The rising awareness among the patients regarding the small cell lung cancer and the availability of advance therapeutics to cure it is expected to drive the demand for the lung cancer therapeutics across the globe.

Distribution Channel Insights

Based on the distribution channel, the hospital pharmacies segment dominated the market in 2025. The increased volume of patient admissions in hospitals for receiving the treatment and diagnosis of cancer has significantly boosted the sales of the lung cancer therapeutics from the hospital pharmacies across the globe. Moreover, the increased preference among the consumers to buy drugs from hospital pharmacies owing to the availability of huge variety drugs has resulted in the dominance of this segment.

The online pharmacies segment is anticipated to be the fastest-growing segment during the forecast period. The rising penetration of the digital media and improving access to the internet has boosted the e-commerce. The rapid emergence of the online pharmacies segment has gained popularity among the customers owing to the ease and conveniences associated with the online pharmacies.

Regional Insights

U.S. Lung Cancer Therapeutics Market Size and Growth 2026 to 2035

The U.S. lung cancer therapeutics market size is exhibited at USD 7.72 billion in 2025 and is projected to be worth around USD 16.98 billion by 2035, growing at a CAGR of 8.20% from 2026 to 2035.

North America was the leading lung cancer therapeutics market in 2025 and it is expected to remain dominant throughout the forecast period. The rising prevalence of lung cancer and growing adoption of advanced diagnosis and lung cancer therapeutics for the treatment of lung cancer has resulted in the increased demand for lung cancer therapeutics in this region. The presence of several top biopharmaceutical companies in this region has immense contributions in the development and growth of the lung cancer therapeutics market. Furthermore, the increased penetration of health insurance in North America, has resulted in the improved access to the advance and costly therapeutics. Moreover the presence of a strong and developed healthcare infrastructure and improved access to the advanced healthcare facilities in the region has significantly contributed towards the growth of the market. The government authority like the US FDA has exponentially worked towards the monitoring and approving various advanced therapies in the region.

Asia Pacific is estimated to exhibit the highest CAGR during the forecast period. The rising prevalence of smoking and exposure to secondhand smoke is resulting in the growing prevalence of lung cancer among the population. The rapidly growing government investments in the development of advanced healthcare facilities and the rising penetration of healthcare insurances in the market has improved the access to advanced healthcare facilities. Furthermore, the rising investments of the top biopharmaceutical companies in the Asia Pacific region to expand their manufacturing facilities and produce advanced drugs at low cost is significantly driving the growth of the market.

Europe: Valuable Support to the Lung Cancer Therapeutics Sector

The European Health Union and Europe's Beating Cancer Plan (EBCP) provided massive funding to support the sector. The EBCP came into force in 2021, along with € 4 billion of funding that introduced the new smart framework for cancer care to hold parity in the treatment and diagnosis areas. Following this Cancer Screening Scheme was an extension that involved lung cancer.

Whereas, the European Health Union delivered aftercare and quality shield to EU citizens' health, which elevated the EU Cancer Screening Recommendation. This nominated lung cancer screening to meet precision therapy and access to the same, bolstering lung cancer therapeutics.

Latin America's Advanced Performance in Lung Cancer Therapeutics

Latin America's advanced performance is visible in the major countries like Chile, Peru, Brazil, Argentina, and Mexico. The countries are the main centre of trials, and Mexico's real-world data is a boon to the lung cancer therapeutics sector. The Latin American Consortium for the Investigation of Lung Cancer (CLICaP) and Latin American Cooperative Oncology Group (LACOG) are beneficial to harmonise the research area and focus on suitable studies.

The advancement is followed by the rising clinical trials and prior unification of precision drugs. With the power of immunotherapies and other fundamental therapies and research partnerships, the regional advanced performance has been more competitive in the global healthcare sector.

Value Chain Analysis of the Lung Cancer Therapeutics Market

• R&D
  The R&D in lung cancer therapeutics particularly aims on personalized medicine, genomic-focused therapies, and immunotherapy. The nanotechnology and AI-inspired discovery is an addition to the R&D sector to enhance the timeframe of the response rate and stimulate early-stage treatment.
  Key Players – Novartis, Bristol Myers Squibb (BMS), and AstraZeneca.
• Clinical Trials and Regulatory Approvals
  The clinical trials are a confirmation or a revision phase to measure the drug's potency level. The trials have hit the transformation with their aim on next-generation tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs).
  Key Players – AbbVie, Amgen, and Roche (Genentech).
• Distribution to Hospitals, Pharmacies
  The growing prevalence of the oncology area needs a skilled and precise oversight because of the crucial infusion-related treatments. The hospitals and pharmacies are the only pathway to serve lung cancer-based therapy to the patient population.
  Key Players – Celgene (BMS), Boehringer Ingelheim, and Eli Lilly and Company.

Competitive Landscape

The lung cancer therapeutics market has evolved due to modern solutions controlling the extreme condition graph. The advantage of precision-targeted therapies in the advanced healthcare sector highlights the initiative of healthcare leaders and their combination of drugs and therapies. The traffic in research and development as well as at the FDA's door indicates the accelerating access to smart solutions for the lung cancer condition. The market giants such as F. Hoffmann-La Roche Ltd (Genentech), Bristol Myers Squibb (BMS), AstraZeneca, Novartis AG and Pfizer Inc. are the strong backbone of modern innovations.

Company Profiles

F. Hoffmann-La Roche Ltd (Genentech)

• HQ: Basel, Switzerland.
• Founded: 1896
• Ownership: Healthcare Company (Genentech is a subsidiary)
• Business Overview: The company's smart business is its drug breakthrough that was witnessed at the FDA's meeting. The massive range of drugs is a long-standing cooperative business for the company and relief for the medical sector seeking a drug solution for the extreme cancer condition.
• Products: Avastin, Rituxan, Herceptin, Activase, etc.
• Geographic Presence: The company's business network is across 150 countries.
• Revenue: The company's 2026 first-half total sales revenue is CHF 30.4 billion.
• Key Strategies: The company's fundamental strategy is to up the game of drug discovery and biotechnology. The modern AI utilization is the primary motive of the company in its drug discovery operation.

Bristol Myers Squibb (BMS)

• HQ: Princeton, New Jersey, United States.
• Founded: 1887
• Ownership: Biopharmaceutical Company
• Business Overview: BMS is famous for breakthroughs that include a robust blending solution of drugs to save millions of lives. The main focus of the company is to serve the patient population with effective drugs, mainly for those stressed individuals struggling with cancer.
• Products: Opdivo, Orencia, Eliquis, etc.
• Geographic Presence: The company's manufacturing, research and commercial activities cover Latin America, Asia Pacific, Europe and North America.
• Revenue: The company's 2025 annual revenue was $48.194 billion, and in 2026 Q1 it earned $11.489 billion.
• Recent Development: In August 2026, BMS confirmed its alliance with Biokin Pharma's iza-bren. Iza-bren is a commendable antibody-drug conjugate. Following this, both companies together announced a positive phase 3 readout. This is a milestone in lung cancer trials.
• Key Strategies: The company's smart strategy is to expand its network by engaging with the top leaders in drug innovations to continue the expertise and trial phases with more confidence.

AstraZeneca

• HQ: Cambridge, United Kingdom.
• Founded: 1999
• Ownership: Science-led multinational biopharmaceutical company.
• Business Overview: AstraZeneca's manufacturing and research and development business brings drug and treatment accessibility across the medical sector. Its groundbreaking drug approvals indicate the quality and constant efforts of the company in great public health management.
• Products: Innovative treatments, vaccines and drugs.
• Geographic Presence: The company expanded its business across 100 countries, involving research and development and manufacturing.
• Revenue: Company's 2026 first half revenue is $30.7 billion.
• Recent Development: In September 2026, AstraZeneca announced its rights to ZegFrovy from Dizal Pharma. This drug is for lung cancer. The company, on its successful upfront payment of $600 million, smartly secured the drug for further lung treatment plans.
• Key Strategies: The company's motive is to explore the innovative possibilities in its existing and new portfolio for what the company is famous for. This consistent sincerity towards modern healthcare highlights the company's dedicated strategy.

Novartis AG

• HQ: Basel, Switzerland.
• Founded: 1996
• Ownership: Healthcare company.
• Business Overview: Novartis' business is to sell innovative and effective prescription drugs. The power of discovery highlights the specialization and creation of drugs by the company. The utilization of technologies and popular branded drugs brings the company into the limelight of the commercial stage.
• Products: Entresto, Kisqali, Tasigna, Consentyx, etc.
• Geographic Presence: The company's sales are across 140 countries.
• Revenue: The company's 2025 revenue was $54.532 billion and is expected to grow in the coming years.
• Key Strategies: The company's strategy is to evolve its drug and tech portfolio as a priority, as medical regulatory compliance is pushing healthcare leaders for an innovative blend that supports modern therapies.

Pfizer Inc.

• HQ: New York, United States.
• Founded: 1849
• Ownership: Biopharmaceutical Company.
• Business Overview: The company's core business highlights the high performance of its top-notch products serving particular therapeutic areas such as neurology, cancer, vaccines, cardiology, and other conditions.
• Products: Paxlovid, Prevnar, Eliquis, Ibrance, etc.
• Geographic Presence: The company's vaccine and drug sales are across 200 territories and countries.
• Revenue: The company's 2025 revenue was $62.58 billion and is expected to grow in the coming years.
• Recent Development: In February 2026, Pfizer introduced its grant recipients, involving funding of $900,000 for modernizing oncology care and innovation mainly in Canada. This funding initiative is a financial push to the awaiting developmental projects.
• Key Strategies: The company focuses on merger and acquisition deals for expanding its drug chain while bolstering its business development. Its specific study and innovation strategies are a boon to the market.

Lung Cancer Therapeutics Market Companies

• AstraZeneca
• BoehringerIngelheim
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche
• Merck & Co
• Pfizer Inc.
• Allergan Inc.
• TevaPharmaceutical Industries Ltd.
• Abbvie, Inc.
• Johnson & Johnson
• Amgen Inc.
• Novartis AG

Recent Developments

The lung cancer therapeutics market is moderately fragmented with the presence of several top players in the market. These market players are constantly engaged in various developmental strategies such as mergers, joint ventures, business expansion, acquisitions, partnerships, collaborations, and new product launches to strengthen their position and expand their market share.

• In March 2019, Adorx Therapeutics entered into a strategic agreement and partnered with Johnson & Johnson Innovation for developing innovative lung cancer therapeutics.
• In May 2021, Amgen acquired the FDA approval for its LUMAKRAS that is used for the treatment of non-small cell lung cancer

Segments Covered in the Report

By Therapy

• Radiation Therapy
• External Beam
• Internal Beam
• Systemic
• Targeted Therapy
• Bevacizumab
• Dabrafenib/Trametinib
• Erlotinib Hydrochloride
• Osimertinib
• Others
• Immunotherapy
• Durvalumab
• Nivolumab
• Atezolizumab
• Pembrolizumab
• Chemotherapy
• Others

By Lung Cancer Type

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Lung Carcinoid Tumor

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Type of Molecule

• Small molecules
• Biologics

By Drug Class

• Alkylating Agents
• Antimetabolites
• EGFR Inhibitors
• Mitotic Inhibitors
• Multikinase Inhibitors
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa